2. Immunology/Inflammation
  3. Complement System
  4. Lampalizumab

Lampalizumab  (Synonyms: RG 7417; TNX 234; Anti-CFD Recombinant Antibody)

Cat. No.: HY-P99298 Purity: 99.46%
COA

Molarity Calculator

Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.

For research use only. We do not sell to patients.

CAS No. : 1278466-20-8

Size Price Stock Quantity
1 mg USD 400 In-stock
5 mg USD 1200 In-stock
10 mg USD 1900 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Lampalizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
IC50 & Target

Factor D[1]
In Vivo

Lampalizumab delivered intravenously to cynomolgus monkeys elicits nearly 10-fold increases in serum Factor D levels within five hours, effectively neutralizing its inhibitory activity[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Molecular Weight

143.8 (kDa)

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Lampalizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Fab-G1-kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lampalizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lampalizumab1278466-20-8RG 7417 TNX 234 Anti-CFD Recombinant AntibodyRG7417RG-7417TNX234TNX 234TNX-234Complement SystemFactor Dage-related macular degenerationAMDmonoclonal antibodycomplement pathwayInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lampalizumab
Cat. No.:
HY-P99298
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.